​
​

NeuroPace (NPCE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NPCE Stock Forecast

NeuroPace stock forecast is as follows: an average price target of $12.88 (represents a 40.15% upside from NPCE’s last price of $9.19) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

NPCE Price Target

The average price target for NeuroPace (NPCE) is $12.88 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $5.50. This represents a potential 40.15% upside from NPCE's last price of $9.19.

NPCE Analyst Ratings

Buy

According to 5 Wall Street analysts, NeuroPace's rating consensus is 'Buy'. The analyst rating breakdown for NPCE stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 2 'Hold' (40.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).

NeuroPace Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 14, 2024Vik ChopraWells Fargo$15.00$7.28106.04%63.22%
May 23, 2024Frank TakkinenLake Street$20.00$7.99150.31%117.63%
Mar 14, 2024Larry BiegelsenWells Fargo$20.00$13.6346.74%117.63%
Nov 10, 2023Ross OsbornCantor Fitzgerald$11.00$7.8540.13%19.70%
Jul 15, 2022-Morgan Stanley$5.50$5.74-4.18%-40.15%
May 13, 2022-Morgan Stanley$6.00$5.960.67%-34.71%
Row per page
Go to

The latest NeuroPace stock forecast, released on Aug 14, 2024 by Vik Chopra from Wells Fargo, set a price target of $15.00, which represents a 106.04% increase from the stock price at the time of the forecast ($7.28), and a 63.22% increase from NPCE last price ($9.19).

NeuroPace Price Target by Period

1M3M12M
# Anlaysts--3
Avg Price Target--$18.33
Last Closing Price$9.19$9.19$9.19
Upside/Downside-100.00%-100.00%99.46%

In the current month, the average price target of NeuroPace stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NeuroPace's last price of $9.19. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Aug 14, 2024Wells FargoOverweightOverweightHold
May 29, 2024Wells FargoOverweightOverweightHold
Mar 14, 2024Wells FargoBuyOverweightUpgrade
Feb 22, 2024Wells FargoBuyBuyHold
Jan 30, 2024Lake StreetUnderperformUnderperformHold
Jan 30, 2024Leerink PartnersBuyBuyHold
Dec 27, 2023Wells FargoBuyBuyHold
Feb 22, 2023Piper Sandler-NeutralInitialise
Feb 22, 2023Cowen & Co.-NeutralInitialise
Feb 22, 2023Lake Street-BuyInitialise
Row per page
Go to

NeuroPace's last stock rating was published by Wells Fargo on Aug 14, 2024. The company gave NPCE a "Overweight" rating, the same as its previous rate.

NeuroPace Financial Forecast

NeuroPace Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
Revenue-------------$16.43M$16.51M$14.47M$12.79M$11.16M$10.20M$11.37M$11.00M$10.34M$12.63M$11.22M
Avg Forecast$28.00M$27.00M$26.00M$23.00M$24.04M$23.20M$22.22M$21.14M$20.92M$19.07M$18.30M$17.33M$17.41M$14.22M$12.63M$12.18M$12.40M$9.90M$11.08M$10.64M$11.00M$10.80M$11.17M$10.98M
High Forecast$29.40M$28.35M$27.30M$24.15M$25.25M$24.36M$23.33M$22.68M$21.37M$20.03M$18.30M$17.33M$18.28M$14.94M$13.26M$12.79M$13.02M$9.90M$11.08M$10.64M$11.00M$10.80M$11.17M$10.98M
Low Forecast$26.49M$25.55M$24.60M$21.76M$22.74M$21.95M$21.02M$19.60M$20.56M$18.04M$18.30M$17.33M$16.47M$13.46M$11.94M$11.52M$11.73M$9.90M$11.08M$10.64M$11.00M$10.80M$11.17M$10.98M
# Analysts111111134211311111111111
Surprise %-------------1.15%1.31%1.19%1.03%1.13%0.92%1.07%1.00%0.96%1.13%1.02%

NeuroPace's average Quarter revenue forecast for Dec 23 based on 3 analysts is $17.41M, with a low forecast of $16.47M, and a high forecast of $18.28M. NPCE's average Quarter revenue forecast represents a 5.98% increase compared to the company's last Quarter revenue of $16.43M (Sep 23).

NeuroPace EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts111111134211311111111111
EBITDA-------------$-5.95M$-7.85M$-8.02M$-9.21M$-9.14M$-10.09M$-8.88M$-8.94M$-6.18M$-6.55M$-6.89M
Avg Forecast$-14.71M$-14.18M$-13.66M$-12.08M$-12.63M$-12.19M$-11.67M$-11.10M$-10.99M$-10.02M$-9.61M$-9.10M$-9.14M$-7.47M$-6.63M$-6.40M$-6.51M$-5.41M$-6.06M$-8.27M$-6.01M$-5.91M$-7.06M$-6.00M
High Forecast$-13.92M$-13.42M$-12.92M$-11.43M$-11.95M$-11.53M$-11.04M$-10.29M$-10.80M$-9.48M$-9.61M$-9.10M$-8.65M$-7.07M$-6.27M$-6.05M$-6.16M$-5.41M$-6.06M$-6.62M$-6.01M$-5.91M$-5.65M$-6.00M
Low Forecast$-15.45M$-14.89M$-14.34M$-12.69M$-13.26M$-12.80M$-12.26M$-11.91M$-11.23M$-10.52M$-9.61M$-9.10M$-9.60M$-7.85M$-6.96M$-6.72M$-6.84M$-5.41M$-6.06M$-9.93M$-6.01M$-5.91M$-8.47M$-6.00M
Surprise %-------------0.80%1.18%1.25%1.41%1.69%1.67%1.07%1.49%1.05%0.93%1.15%

undefined analysts predict NPCE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NeuroPace's previous annual EBITDA (undefined) of $NaN.

NeuroPace Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts111111134211311111111111
Net Income-------------$-7.26M$-9.12M$-14.40M$-12.43M$-13.37M$-14.41M$-13.16M$-8.83M$-8.08M$-8.49M$-8.81M
Avg Forecast$-2.94M$-3.24M$-4.12M$-5.89M$-5.89M$-6.24M$-6.89M$-7.30M$-7.28M$-7.91M$-8.83M$-9.46M$-9.27M$-11.90M$-13.84M$-13.47M$-14.72M$-15.22M$-12.98M$-10.68M$-9.52M$-8.77M$-9.15M$-6.83M
High Forecast$-2.74M$-3.01M$-3.83M$-5.48M$-5.48M$-5.81M$-6.41M$-6.22M$-6.69M$-7.35M$-8.21M$-8.80M$-8.43M$-11.06M$-12.87M$-12.53M$-13.69M$-15.22M$-12.98M$-8.54M$-9.52M$-8.77M$-7.32M$-6.83M
Low Forecast$-3.14M$-3.45M$-4.39M$-6.27M$-6.27M$-6.65M$-7.34M$-8.11M$-7.86M$-8.42M$-9.41M$-10.08M$-10.12M$-12.67M$-14.74M$-14.35M$-15.68M$-15.22M$-12.98M$-12.82M$-9.52M$-8.77M$-10.98M$-6.83M
Surprise %-------------0.61%0.66%1.07%0.84%0.88%1.11%1.23%0.93%0.92%0.93%1.29%

NeuroPace's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NPCE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

NeuroPace SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts111111134211311111111111
SG&A-------------$13.39M$14.48M$13.43M$13.57M$12.55M$12.77M$12.44M-$9.42M$9.53M$8.27M
Avg Forecast$24.15M$23.28M$22.42M$19.84M$20.73M$20.01M$19.16M$18.23M$18.04M$16.45M$15.78M$14.94M$15.01M$12.27M$10.89M$10.50M$10.69M$8.54M$9.56M$9.18M$9.49M$9.31M$10.26M$9.47M
High Forecast$25.36M$24.45M$23.55M$20.83M$21.77M$21.01M$20.12M$19.56M$18.43M$17.27M$15.78M$14.94M$15.77M$12.88M$11.43M$11.03M$11.23M$8.54M$9.56M$9.18M$9.49M$9.31M$12.31M$9.47M
Low Forecast$22.85M$22.03M$21.21M$18.77M$19.61M$18.93M$18.13M$16.90M$17.73M$15.56M$15.78M$14.94M$14.20M$11.61M$10.30M$9.93M$10.12M$8.54M$9.56M$9.18M$9.49M$9.31M$8.21M$9.47M
Surprise %-------------1.09%1.33%1.28%1.27%1.47%1.34%1.36%-1.01%0.93%0.87%

NeuroPace's average Quarter SG&A projection for Dec 23 is $15.01M, based on 3 Wall Street analysts, with a range of $14.20M to $15.77M. The forecast indicates a 12.14% rise compared to NPCE last annual SG&A of $13.39M (Sep 23).

NeuroPace EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts111111134211311111111111
EPS-------------$-0.28$-0.36$-0.57$-0.50$-0.54$-0.59$-0.54$-0.37$-0.34$-0.48$-0.40
Avg Forecast$-0.10$-0.11$-0.14$-0.20$-0.20$-0.21$-0.23$-0.25$-0.25$-0.27$-0.30$-0.32$-0.31$-0.40$-0.47$-0.46$-0.50$-0.53$-0.45$-0.44$-0.33$-0.30$-0.34$-0.24
High Forecast$-0.09$-0.10$-0.13$-0.19$-0.19$-0.20$-0.22$-0.21$-0.23$-0.25$-0.28$-0.30$-0.29$-0.38$-0.44$-0.43$-0.46$-0.53$-0.45$-0.44$-0.33$-0.30$-0.34$-0.24
Low Forecast$-0.11$-0.12$-0.15$-0.21$-0.21$-0.23$-0.25$-0.28$-0.27$-0.29$-0.32$-0.34$-0.34$-0.43$-0.50$-0.49$-0.53$-0.53$-0.45$-0.44$-0.33$-0.30$-0.34$-0.24
Surprise %-------------0.69%0.77%1.25%1.00%1.02%1.31%1.22%1.12%1.12%1.43%1.67%

According to undefined Wall Street analysts, NeuroPace's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NPCE previous annual EPS of $NaN (undefined).

NeuroPace Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
NVRONevro$4.23$32.72673.52%Hold
LUNGPulmonx$6.20$11.9392.42%Buy
KIDSOrthoPediatrics$25.50$39.6055.29%Buy
NPCENeuroPace$9.19$12.8840.15%Buy
CNMDCONMED$70.69$96.0035.80%Buy
OFIXOrthofix Medical$18.87$24.0027.19%-
CVRXCVRx$13.52$16.3320.78%Buy
IRMDIRadimed$52.08$60.0015.21%Buy
AORTArtivion$27.17$30.6012.62%Buy
FNAParagon 28$10.35$11.5011.11%Buy
ITGRInteger$133.37$138.003.47%Buy
SRDXSurmodics$39.17$39.500.84%Buy
GKOSGlaukos$141.44$123.44-12.73%Buy

NPCE Forecast FAQ

Is NeuroPace a good buy?

Yes, according to 5 Wall Street analysts, NeuroPace (NPCE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of NPCE's total ratings.

What is NPCE's price target?

NeuroPace (NPCE) average price target is $12.88 with a range of $5.5 to $20, implying a 40.15% from its last price of $9.19. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will NeuroPace stock go up soon?

According to Wall Street analysts' prediction for NPCE stock, the company can go up by 40.15% (from the last price of $9.19 to the average price target of $12.88), up by 117.63% based on the highest stock price target, and down by -40.15% based on the lowest stock price target.

Can NeuroPace stock reach $14?

NPCE's highest twelve months analyst stock price target of $20 supports the claim that NeuroPace can reach $14 in the near future.

What are NeuroPace's analysts' financial forecasts?

NeuroPace's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $90.6M (high $95.63M, low $85.32M), average EBITDA is $-47.591M (high $-44.815M, low $-50.231M), average net income is $-26.323M (high $-23.909M, low $-28.375M), average SG&A $78.13M (high $82.47M, low $73.58M), and average EPS is $-0.894 (high $-0.812, low $-0.964). NPCE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $104M (high $109.22M, low $98.4M), average EBITDA is $-54.63M (high $-51.686M, low $-57.371M), average net income is $-16.195M (high $-15.06M, low $-17.25M), average SG&A $89.69M (high $94.19M, low $84.86M), and average EPS is $-0.55 (high $-0.511, low $-0.586).

Did the NPCE's actual financial results beat the analysts' financial forecasts?

Based on NeuroPace's last annual report (Dec 2023), the company's revenue was $65.42M, beating the average analysts forecast of $56.43M by 15.93%. Apple's EBITDA was $-27.174M, missing the average prediction of $-29.644M by -8.33%. The company's net income was $-32.956M, missing the average estimation of $-48.479M by -32.02%. Apple's SG&A was $54.52M, beating the average forecast of $48.67M by 12.02%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.646 by -99.92%. In terms of the last quarterly report (Sep 2023), NeuroPace's revenue was $16.43M, beating the average analysts' forecast of $14.22M by 15.48%. The company's EBITDA was $-5.95M, missing the average prediction of $-7.472M by -20.37%. NeuroPace's net income was $-7.257M, missing the average estimation of $-11.896M by -38.99%. The company's SG&A was $13.39M, beating the average forecast of $12.27M by 9.13%. Lastly, the company's EPS was $-0.28, missing the average prediction of $-0.404 by -30.69%